Monopar Therapeutics Inc. Common Stock
MNPRMonopar Therapeutics Inc. (MNPR) is a biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company aims to advance innovative drug candidates through clinical development with a focus on improving patient outcomes, often emphasizing repurposing existing drugs for new therapeutic applications.
Company News
Monopar Therapeutics presented new data at AASLD showing that ALXN1840 (tiomolybdate choline) rapidly improved copper balance in Wilson disease patients through increased fecal copper excretion.
Monopar Therapeutics is conducting a $135 million underwritten offering of common stock and pre-funded warrants, with plans to use proceeds for general corporate purposes and a stock repurchase from Tactic Pharma.
Monopar Therapeutics published a Letter to the Editor in the Journal of Hepatology, reanalyzing their Phase 2 ALXN1840-WD-204 study for Wilson disease. The new analysis shows that ALXN1840 statistically significantly improved copper balance by accounting for additional routes of copper loss.
Monopar Therapeutics has in-licensed ALXN-1840, a late-stage drug candidate for Wilson disease, from Alexion, AstraZeneca Rare Disease. The company also has two novel radiopharma clinical trials active and enrolling patients with advanced solid cancers.
Monopar Therapeutics, a clinical-stage biotechnology company, announced the pricing of a $19.2 million public offering of its common stock at $16.25 per share. The proceeds will be used for general corporate purposes, including research and development, clinical trials, and working capital.
